---
authors:
- Ebell, Mark H
category: Case Study
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/36920834/
file_path: 2023/03/nirmatrelvirritonavir-reduces-hospitalization-mortality-in-p.md
issue: '3'
keywords:
- Humans
- Ritonavir
- Antiviral Agents
- Hospitalization
- COVID-19 Drug Treatment
- COVID-19
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Ritonavir
- COVID-19
- COVID-19 Drug Treatment
- Hospitalization
- Antiviral Agents
original_format: PubMed
pages: '316'
patient_population: Adults
peer_reviewed: true
pmid: '36920834'
processed_date: '2025-07-30'
publication_date: '2023-03-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-07-30'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Nirmatrelvir/Ritonavir Reduces Hospitalization, Mortality in Patients 65 Years and Older With COVID-19; Effect on Younger
  Patients Unclear.
topics:
- Family Medicine
volume: '107'
---

# Nirmatrelvir/Ritonavir Reduces Hospitalization, Mortality in Patients 65 Years and Older With COVID-19; Effect on Younger Patients Unclear.

**Authors:** Ebell, Mark H

**Published in:** American family physician | Vol. 107, No. 3 | 2023-03-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/36920834/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Ritonavir, COVID-19, COVID-19 Drug Treatment, Hospitalization, Antiviral Agents

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/36920834/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
